Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Zalicus, Inc. (“Zalicus”) (NasdaqCM: ZLCS) related to the merger with Epirus Biopharmaceuticals for shareholders. Under the terms of the definitive agreement, Zalicus shareholders will own an unknown percentage of the combined company subject to adjustment based on the level of Zalicus’ net cash at closing.

If you are an affected investor, and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at, or Patrick Powers at Powers Taylor LLP, toll free (877) 728-9607, via e-mail at There is no cost or fee to you.

The Zalicus investigation centers on whether Zalicus’ Board of Directors is acting in the shareholders’ best interests, whether the board is properly considering the proposed price for the shareholders, and whether the board has employed an adequate process to review and act on the proposed transaction. In particular, the actual amount of compensation to be paid to ZLCS shareholders is not known because the final consideration paid will be determined through an adjustment based on the amount of Zalicus net cash. However, based on Zalicus’ net cash on the day of the buyout announcement, ZLCS shareholders will only be paid an aggregate of 14% of the combined company.

The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.

Copyright Business Wire 2010